

May 9<sup>th</sup>, 2022

Company name: Fukuda Denshi Co., Ltd.  
 Representative: Daijiro Shirai, President & COO  
 Standard Market of the Tokyo Stock Exchange  
 code no.: 6960  
 Inquiries: Business Planning Department  
 Telephone: +81-3-5684-1558

## Notice of the Forecast of the Financial Results for the Fiscal Year Ending March 2022

Fukuda Denshi has revised the forecasts of the financial results for the fiscal year ending March 31<sup>st</sup>, 2022 based on the recent business conditions.

### 1. Forecast of consolidated financial results for the fiscal year ending March 2022 (April 1<sup>st</sup>, 2021 through March 31<sup>st</sup>, 2022)

(% represents increase or decrease from the previous forecast)

|                                   | Net sales   | Operating Profit | Ordinary Profit | Profit attributable to owners of parent | Earnings per share |
|-----------------------------------|-------------|------------------|-----------------|---|--------------------|
|                                   | million yen | million yen      | million yen     | million yen                             | yen                |
| Previous forecast (A)             | 125,000     | 20,000           | 20,500          | 15,000                                  | 991.96             |
| This forecast (B)                 | 132,000     | 22,600           | 23,300          | 16,100                                  | 1,064.70           |
| Fluctuation sum (B-A)             | +7,000      | +2,600           | +2,800          | +1,100                                  |                    |
| Fluctuation rate (%)              | +5.6        | +13.0            | +13.6           | +7.3                                    |                    |
| (Rf) Previous FY ended March 2021 | 146,756     | 19,811           | 20,264          | 14,716                                  | 973.33             |

### 2. Reasons for revisions

The forecast of consolidated “Net sales” is expected to be 132,000 million yen (up 7,000 million yen, from the previous forecast) due to the sales growth of COVID-19 related products with the continuing medical demand.

Also, “Operating Profit”, “Ordinary Profit” and “Profit attributable to owners of parent” are most likely exceeding the previous forecast, due to the favorable product mix.

#### ※Note

The forecasted financial results described above are based on information available as of the release date of this announcement. Actual results may differ from the results projected and presented hereby for a variety of reasons.

It will be promptly announced as soon as the revision of the forecast is needed.

※This English translation is for reference purposes only. The original Japanese version will prevail as the official authoritative version.

※The original disclosure in Japanese was released on May 9<sup>th</sup>, 2022 at 17:35 (GMT+9)